Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5
作者：
Cao, Yi [1 ,2 ]
Li, Yunjin [1 ,2 ]
Liu, Ruijie [1 ]
Zhou, Jianhua [1 ,2 ]
Wang, Kuansong [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China
来源：
CANCERS | 2023年 / 15卷 / 09期
基金：
中国国家自然科学基金;
关键词：
HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;
D O I：
10.3390/cancers15092568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.
引用
收藏
页数：27
相关论文
共 137 条
[91]   Cullin-RING E3 Ubiquitin Ligase 7 in Growth Control and Cancer [J].
Pan, Zhen-Qiang .
CULLIN-RING LIGASES AND PROTEIN NEDDYLATION: BIOLOGY AND THERAPEUTICS, 2020, 1217 :285-296
[92]   Eph receptors and ephrins in cancer: bidirectional signalling and beyond [J].
Pasquale, Elena B. .
NATURE REVIEWS CANCER, 2010, 10 (03) :165-180
[93]   Signaling through scaffold, anchoring, and adaptor proteins [J].
Pawson, T ;
Scott, JD .
SCIENCE, 1997, 278 (5346) :2075-2080
[94]   Hsp90 and Cdc37 - a chaperone cancer conspiracy [J].
Pearl, LH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :55-61
[95]   Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K/Akt pathway [J].
Pei, Lei ;
Kong, Yirong ;
Shao, Changfeng ;
Yue, Xiao ;
Wang, Zongling ;
Zhang, Na .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (11) :5311-5321
[96]   Mapping Bromodomains in breast cancer and association with clinical outcome [J].
Perez-Pena, Javier ;
Paez, Raquel ;
Nieto-Jimenez, Cristina ;
Corrales Sanchez, Veronica ;
Galan-Moya, Eva M. ;
Pandiella, Atanasio ;
Gyorffy, Balazs ;
Ocana, Alberto .
SCIENTIFIC REPORTS, 2019, 9 (1)
[97]  
Pistilli B, 2020, J CLIN ONCOL, V38
[98]   Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway [J].
Qiu, Ni ;
He, Yu-fang ;
Zhang, Si-ming ;
Zhan, Yong-tao ;
Han, Guo-dong ;
Jiang, Ming ;
He, Wei-xing ;
Zhou, Jie ;
Liang, Hong-ling ;
Ao, Xiang ;
Xia, Hao-ming ;
Li, Jia ;
Yang, Yu-yang ;
He, Zhi-min ;
Zou, Zheng-zhi ;
Li, Hong-sheng .
CANCER LETTERS, 2019, 464 :25-36
[99]   Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer [J].
Qiu, Yan ;
Yang, Libo ;
Liu, Honghong ;
Luo, Xiaobo .
STEM CELLS, 2021, 39 (09) :1125-1136
[100]   Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma [J].
Ramamoorthi, Ganesan ;
Kodumudi, Krithika ;
Snyder, Colin ;
Grover, Payal ;
Zhang, Hongtao ;
Greene, Mark, I ;
Basu, Amrita ;
Gallen, Corey ;
Wiener, Doris ;
Costa, Ricardo L. B. ;
Han, Hyo S. ;
Koski, Gary ;
Czerniecki, Brian J. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
567891011121314